MCM
ARKG icon

Mainstay Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Mainstay Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-67,186
Closed -$5.96M – 126
2021
Q1 		$5.96M Sell
67,186
-397,187
-86% -$39.4M 1.84% 10
2020
Q4 		$43.3M Buy
464,373
+5,849
+1% +$466K 12.67% 1
2020
Q3 		$29.2M Buy
458,524
+54,451
+13% +$3.19M 7.64% 5
2020
Q2 		$21.1M Buy
404,073
+394,502
+4,122% +$16.9M 6.13% 6
2020
Q1 		$289K Buy
+9,571
New +$320K 0.09% 78

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SDH
Sloy Dahl & Holst Vancouver, Washington $728M AUM 37.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Mainstay Capital Management's ARKG Position: Q2 2021 in Review

Mainstay Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2021, closing a stake of 67,186 shares — an estimated $5.96M sold.

Mainstay Capital Management first reported a position in ARKG in Q1 2020 and held it in 5 quarters. The position peaked at $43.3M in Q4 2020. 513 funds tracked by Wall St. Rank hold ARKG as of Q2 2021.

  • Mainstay Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q2 2021 after selling out during the quarter.
  • Mainstay Capital Management sold 67,186 ARK Genomic Revolution ETF shares in Q2 2021, an estimated $5.96M.
  • Mainstay Capital Management first reported a position in ARK Genomic Revolution ETF in Q1 2020 and held it in 5 quarters.
  • Mainstay Capital Management's ARK Genomic Revolution ETF position peaked at $43.3M in Q4 2020.
  • 513 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2021.

Based on Mainstay Capital Management's 13F filing for Q2 2021, filed 6 Aug 2021.